HPMA copolymer-collagen hybridizing peptide conjugates targeted to breast tumor extracellular matrix.


Journal

Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908

Informations de publication

Date de publication:
01 2023
Historique:
received: 02 06 2022
revised: 04 10 2022
accepted: 09 10 2022
pubmed: 17 10 2022
medline: 3 2 2023
entrez: 16 10 2022
Statut: ppublish

Résumé

The extracellular matrix (ECM) is dynamically involved in many aspects of cell growth and survival, and it plays an active role in cancer etiology. In comparison to healthy ECM, tumor associated ECM shows high collagen deposition and remodeling activity, which results in an increased amount of denatured collagen strands in tumor tissues. Capitalizing on this distinguishing feature, we developed tumor-localizing polymeric carriers that selectively bind to denatured collagen in the tumor ECM. We synthesized N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers with their side chains conjugated to collagen hybridizing peptides (CHPs). HPMA copolymer-CHP conjugates exhibited selective affinity to denatured collagen and localized to tumors in an orthotopic MDA-MB-231 murine breast cancer model. The conjugates had increased tumor localization compared to copolymers with scrambled peptides in the side chains, as well as increased retention compared to free CHPs. Such conjugates show promise as carriers for ECM-acting drugs and imaging agents in the management of diseases characterized by high ECM remodeling activity.

Identifiants

pubmed: 36244509
pii: S0168-3659(22)00687-3
doi: 10.1016/j.jconrel.2022.10.017
pii:
doi:

Substances chimiques

hydroxypropyl methacrylate UKW89XAX2X
Methacrylates 0
Peptides 0
Collagen 9007-34-5

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

278-288

Subventions

Organisme : NIH HHS
ID : R21 OD026618
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA042014
Pays : United States

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Auteurs

Nithya Subrahmanyam (N)

Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112 United States of America; Utah Center for Nanomedicine, University of Utah, Salt Lake City, UT 84112, United States of America.

Bhuvanesh Yathavan (B)

Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112 United States of America; Utah Center for Nanomedicine, University of Utah, Salt Lake City, UT 84112, United States of America.

Julian Kessler (J)

Department of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, United States of America.

S Michael Yu (SM)

Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112 United States of America; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, United States of America. Electronic address: michael.yu@utah.edu.

Hamidreza Ghandehari (H)

Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112 United States of America; Utah Center for Nanomedicine, University of Utah, Salt Lake City, UT 84112, United States of America; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, United States of America. Electronic address: hamid.ghandehari@utah.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH